Tamoxifen Therapy for Breast Cancer and Endometrial Pathology
- PMID: 27407795
- PMCID: PMC4922966
- DOI: 10.1016/S0377-1237(05)80052-8
Tamoxifen Therapy for Breast Cancer and Endometrial Pathology
Abstract
Background: Tamoxifen, used as adjuvant therapy for carcinoma breast in postmenopausal women to prevent relapse has estrogenic effect on the endometrium.
Methods: 104 patients on tamoxifen for more than six months were subjected to a clinical examination and transvaginal sonography. Patients with endometrial thickness > 8 mm were further evaluated by hysteroscopy and endometrial biopsy.
Results: 35(34%) patients were symptomatic. The average endometrial thickness was 11.2 mm which correlated with duration of tamoxifen use. 27(48%) patients had abnormal hysteroscopic findings. 35 (63%) of endometrial biopsies revealed abnormal endometrium. One case of endometrial carcinoma was diagnosed. The results were statistically analysed. There is a significant association between symptomatic status and endometrial thickness and duration of tamoxifen use.
Conclusion: All patients on long term tamoxifen should be annually screened for endometrial pathology.
Keywords: Endometrium; Tamoxifen; Transvaginal sonography.
Similar articles
-
Transvaginal endometrial sonography in postmenopausal women taking tamoxifen.Obstet Gynecol. 1999 Mar;93(3):363-6. doi: 10.1016/s0029-7844(98)00418-9. Obstet Gynecol. 1999. PMID: 10074980
-
Sonographic, hysteroscopic, and histologic evaluation of the endometrium in postmenopausal women with breast cancer receiving tamoxifen.J Am Assoc Gynecol Laparosc. 2000 Feb;7(1):77-81. doi: 10.1016/s1074-3804(00)80013-4. J Am Assoc Gynecol Laparosc. 2000. PMID: 10648743
-
Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen.J Am Assoc Gynecol Laparosc. 1997 May;4(3):331-9. doi: 10.1016/s1074-3804(05)80224-5. J Am Assoc Gynecol Laparosc. 1997. PMID: 9154782
-
Ultrasonographic evaluation of the endometrium in postmenopausal vaginal bleeding.Radiol Clin North Am. 2003 Jul;41(4):769-80. doi: 10.1016/s0033-8389(03)00060-5. Radiol Clin North Am. 2003. PMID: 12899491 Review.
-
Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement.J Ultrasound Med. 2001 Oct;20(10):1025-36. doi: 10.7863/jum.2001.20.10.1025. J Ultrasound Med. 2001. PMID: 11587008 Review.
Cited by
-
Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy.J Midlife Health. 2015 Apr-Jun;6(2):59-65. doi: 10.4103/0976-7800.158947. J Midlife Health. 2015. PMID: 26167055 Free PMC article.
-
Uterine changes during tamoxifen, toremifene, and other therapy for breast cancer: evaluation with magnetic resonance imaging.Jpn J Radiol. 2010 Jul;28(6):430-6. doi: 10.1007/s11604-010-0446-9. Epub 2010 Jul 27. Jpn J Radiol. 2010. PMID: 20661693
References
-
- Burgmann EJ, Goodman A. Surveillance for Endometrial Cancer in women receiving tamoxifen. Annals of Internal Medicine. 1999;131:127–135. - PubMed
-
- Ozsener S, Itil I, Dikmen Y. Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen. Eur J Gynaecol Oncol. 1998;19(6):580–583. - PubMed
-
- Hann LE, Bach AM, Tao Y, Baum HJ, Barakat RR. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathological findings. Am J Roentgenol. 1997;168(3):657–661. - PubMed
-
- Katase K, Sugiyama Y, Hasumi K, Yoshimoto M, Kasumi F. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Cancer. 1998;82(9):1698–1703. - PubMed
-
- Peters-Engl C, Frank W, Danmayr E, Friedl HP, Leodolter S, Medl M. Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res Treat. 1999;54(3):255–260. - PubMed
LinkOut - more resources
Full Text Sources
